Sagong M, et al. - In this 5-year, prospective, observational, multicenter, open-label, single-arm, global study (LUMINOUS), researchers sought to assess the real-world effectiveness, treatment patterns, and safety of ranibizumab, a humanized monoclonal antibody Fab fragment specifically designed for ocular use, in Korean patients with neovascular age-related macular degeneration (nAMD). Adults aged ≥ 18 years who were either treatment-naïve or prior-treated were registered and treated with ranibizumab 0.5 mg as per the local label. The sample consisted of 367 Korean patients with nAMD (152 treatment-naïve and 215 prior-treated). The LUMINOUS study confirms real-world efficacy and safety of ranibizumab in Korean patients with nAMD; factors such as age, baseline visual acuity (VA), and loading-dose were associated with VA gain one year after treatment.